Okamoto H, Ito O, Roman R J, Hudetz A G
Department of Anesthesiology, Medical College of Wisconsin, Milwaukee 53226, USA.
Stroke. 1998 Jun;29(6):1209-18. doi: 10.1161/01.str.29.6.1209.
Bacterial lipopolysaccharide (LPS), an endotoxin, has been reported to induce the expression of inducible isoforms of both nitric oxide synthase (iNOS) and cyclooxygenase (COX-2) in various cell types. LPS is also known to dilate systemic vasculature, including cerebral vessels. This study aimed to determine to what extent LPS induces iNOS and COX-2 expression in the brain and whether NO and/or cyclooxygenase metabolites derived from iNOS and/or COX-2 contribute to the LPS-induced cerebral hyperemia.
Regional cerebral blood flow (rCBF) was measured by laser-Doppler flowmetry in halothane-anesthetized, artificially ventilated rats for 4 hours after intracerebroventricular administration of LPS.
LPS at doses of 0.01 mg/kg to 1 mg/kg caused dose-dependent, progressive increases in rCBF at 1 to 4 hours after administration. The increase in rCBF was attenuated by systemic administration of the selective iNOS inhibitor aminoguanidine (100 mg/kg IP) or the selective COX-2 inhibitor NS-398 (5 mg/kg IP), and it was abolished by preventing induction of these isoforms with dexamethasone (4 mg/kg IP). LPS significantly increased iNOS and COX-2 mRNA, iNOS protein, and iNOS and cyclooxygenase enzyme activity. The increases in iNOS and cyclooxygenase enzyme activity were eliminated by aminoguanidine and NS-398, respectively. Dexamethasone also prevented the increase in iNOS and cyclooxygenase activity.
These results indicate that induction of iNOS and COX-2 expression and the increased production of NO and vasodilator prostanoids in the brain contribute to the elevation in CBF after intracerebroventricular administration of LPS.
细菌脂多糖(LPS)作为一种内毒素,据报道可在多种细胞类型中诱导一氧化氮合酶(iNOS)和环氧化酶(COX-2)诱导型同工型的表达。LPS还已知可扩张包括脑血管在内的全身血管。本研究旨在确定LPS在多大程度上诱导大脑中iNOS和COX-2的表达,以及源自iNOS和/或COX-2的NO和/或环氧化酶代谢产物是否促成LPS诱导的脑充血。
在氟烷麻醉、人工通气的大鼠脑室内注射LPS后4小时,通过激光多普勒血流仪测量局部脑血流量(rCBF)。
剂量为0.01mg/kg至1mg/kg的LPS在给药后1至4小时引起rCBF剂量依赖性、渐进性增加。全身性给予选择性iNOS抑制剂氨基胍(100mg/kg腹腔注射)或选择性COX-2抑制剂NS-398(5mg/kg腹腔注射)可减弱rCBF的增加,而用地塞米松(4mg/kg腹腔注射)阻止这些同工型的诱导可消除rCBF的增加。LPS显著增加iNOS和COX-2 mRNA、iNOS蛋白以及iNOS和环氧化酶活性。氨基胍和NS-398分别消除了iNOS和环氧化酶活性的增加。地塞米松也阻止了iNOS和环氧化酶活性的增加。
这些结果表明,脑室内注射LPS后,大脑中iNOS和COX-2表达的诱导以及NO和血管舒张性前列腺素生成的增加促成了CBF的升高。